NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. NV-387's proposed mechanism targets viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
The announcement comes as health authorities work to contain the outbreak of the Bundibugyo ebolavirus, a strain that has caused previous outbreaks in the region. NanoViricides emphasized that NV-387's broad-spectrum activity could be critical in addressing not only Ebola but also other viral diseases. The drug candidate is currently being developed for multiple indications, including respiratory syncytial virus (RSV), COVID-19, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles.
NV-387 is a nanoviricide drug candidate that does not encapsulate remdesivir; however, the company also has a version called NV-CoV-2-R that encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, the encapsulated version could be an approvable drug if safety is comparable. NanoViricides is also developing drugs against a range of viral diseases, including oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus.
The company's platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for this technology for several drugs targeting specific mechanisms for human viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, Asian bird flu, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses.
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. However, as with any drug development, there are significant risks and uncertainties. The company notes that the path to typical drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
For more information, visit the company's newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/mm3Z5.